Fungal Infection Clinical Trial
Official title:
A Multicenter, Open Label Pharmacokinetic Study of Fluconazole in Infants
The purpose of this study is to determine the pharmacokinetics of fluconazole in infants and evaluate the dose exposure relationship of current fluconazole dosing in infants who are receiving fluconazole for the prevention or treatment of systemic fungal infections.
Systemic fungal infections in neonates are associated with high morbidity and mortality. The increasing use of intravenous central catheters, parenteral nutrition, and antibiotics in neonatal intensive care units has contributed not only to improved survival but also to the increasing incidence of fungal sepsis particularly in preterm infants. Decreasing fungal colonization can decrease the risk of systemic fungal infection. Fluconazole is a potent antifungal agent in the triazole family. Fluconazole has been shown to reduce the risk of fungal colonization and systemic infection however we do not have sufficient pharmacokinetic information in neonates to support dosing guidelines. In this study, we will perform a population pharmacokinetic study in neonates receiving fluconazole as standard of care. Fluconazole levels will be measured using a liquid chromatography/tandem mass spectroscopy (LC/MS/MS) assay from very small quantities of blood appropriate for neonates. Pharmacokinetic data obtained in this study will support appropriate dosing of fluconazole in neonates and provide information regarding drug metabolism in neonates. ;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03641131 -
Ampholipad Real-World Data in Taiwan
|
||
| Not yet recruiting |
NCT03292224 -
Systemic Fungal Infections in ICU Patients
|
N/A | |
| Completed |
NCT01371656 -
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
|
Phase 3 | |
| Completed |
NCT00936117 -
Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia
|
Phase 2 | |
| Completed |
NCT00740389 -
TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.
|
Phase 1 | |
| Completed |
NCT03857399 -
Empiric Therapy of Patients With Persistent Fever and Agranulocytosis Using Caspofungin
|
Phase 2 | |
| Not yet recruiting |
NCT04215458 -
Microbiota in Skin and Mucosa of Patients With Inflammatory Skin Diseases
|
N/A | |
| Completed |
NCT03667690 -
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
|
Phase 3 | |
| Completed |
NCT02957929 -
Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally
|
Phase 1 | |
| Completed |
NCT01419678 -
Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients
|
N/A | |
| Recruiting |
NCT00333645 -
Prophylaxis With Caspofungin in High-Risk Liver Transplantation
|
Phase 2 | |
| Not yet recruiting |
NCT03650439 -
Fungal Infections in Patients With Hematological Malignancies
|
||
| Completed |
NCT01303549 -
Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients
|
Phase 4 | |
| Completed |
NCT00811642 -
Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)
|
Phase 3 | |
| Withdrawn |
NCT00430469 -
Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients
|
Phase 1/Phase 2 | |
| Terminated |
NCT00386997 -
ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia
|
Phase 4 | |
| Completed |
NCT04166669 -
A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001
|
Phase 1 | |
| Recruiting |
NCT05150327 -
Multicenter Cohort Study of Invasive Fungal Filamentous Fungal Infections in Liver Transplant Patients
|
||
| Completed |
NCT02387983 -
Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)
|
Phase 1 | |
| Completed |
NCT02956499 -
Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects
|
Phase 1 |